OnDemand WTP Pricing Research

Sandoz pays $12.6 million to settle false drug pricing allegations | PharmaTimes

The CMS uses this information to set payment amounts for most drugs covered under Medicare Part B. Inaccurate pricing information can cause Medicare to overpay for these drugs. Pricing data is also used to calculate rebates that manufacturers pay to the States in connection with the Medicaid programme.

“Sandoz’s misrepresentations undermined the integrity of the Medicare Part B drug pricing system,” said the HHS Office of Inspector General chief counsel, Gregory Demske.

He added: “The Medicare programme relies on drug manufacturers to accurately report pricing information. We hope today’s settlement reinforces for these companies the importance of taking their drug price reporting responsibilities seriously. We will continue to penalise manufacturers that misrepresent or fail to timely file the required information.”

Read complete article here:

Sandoz pays $12.6 million to settle false drug pricing allegations.

1 Comment on "Sandoz pays $12.6 million to settle false drug pricing allegations | PharmaTimes"

Trackback | Comments RSS Feed

Inbound Links

  1. Pricing News Daily > 3/25/15 : Pricing News | 2015/03/25

Post a Comment

WP-SpamFree by Pole Position Marketing